Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-19
2006-09-19
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S027000, C514S211070, C514S252010, C514S282000, C514S643000, C514S717000, C424S094600
Reexamination Certificate
active
07109161
ABSTRACT:
The present invention is directed to the use of benzethonium chloride, alone or in combination with phenoxyethanol or phenyl ethyl alcohol, to provide anti-microbial activity in pharmaceutical compositions. The present invention also provides methods of using benzethonium chloride, alone or in combination with phenoxyethanol or phenyl ethyl alcohol, to inhibit microbial growth in pharmaceutical compositions.
REFERENCES:
patent: 3489837 (1970-01-01), Hyman
patent: 4053628 (1977-10-01), Stevenson et al.
patent: 4377513 (1983-03-01), Sugimoto et al.
patent: 4506018 (1985-03-01), North, Jr.
patent: 4703008 (1987-10-01), Lin
patent: 4806524 (1989-02-01), Kawaguchi et al.
patent: 5045529 (1991-09-01), Chiang
patent: 5503827 (1996-04-01), Woog et al.
patent: 5597560 (1997-01-01), Bergamini et al.
patent: 5661125 (1997-08-01), Strickland
patent: 5863562 (1999-01-01), Tsao et al.
patent: 6022551 (2000-02-01), Jampani et al.
patent: 0 199 992 (1986-11-01), None
patent: 0 459 795 (1991-05-01), None
patent: 0 930 065 (1999-07-01), None
patent: 01/07075 (2001-02-01), None
patent: 01/07086 (2001-02-01), None
Drug Facts and Comparisons 2000, 54th ed., pp. 698, 1319, 1330.
Merck Index, 11th ed., pp. 7228 and 1084 (1989).
U.S. Appl. No. 10/031,947, entitled “Multi-Dose Erythropoietin Formulations” by Atef Gayed filed May 15, 2002.
International Search Report dated Nov. 10, 2000.
Miyake, et al., “Purification of Human Erythropoietin,”J. Biol. Chem., 252(15):5558-67 (1997).
Sherwood, et al., “Erythropoietin Production by Human Renal Carcinoma Cells in Culture,”Endocrinology, 99(2):504-10 (1976).
Sherwood, et al., “Establishment of Human Erythropoietin-Producing Renal Carcinoma Cell Line,”Clinical Research, 31:323A (1983).
Durieux, Marcel E., M.D., “Synergistic Inhibition of Muscarinic Signaling by Ketamine Stereoisomers and the Preservative Benzethonium Chloride,”Anesthesiology86:1326-33 (1997).
Aventis Pharmaceuticals Inc.
Henley III Raymond J.
Vinson & Elkins L.L.P.
LandOfFree
Preserved pharmaceutical formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preserved pharmaceutical formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preserved pharmaceutical formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3594322